Granite Investment Partners LLC raised its stake in shares of Cambrex Corporation (NYSE:CBM) by 7.8% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 229,344 shares of the biotechnology company’s stock after buying an additional 16,617 shares during the period. Granite Investment Partners LLC’s holdings in Cambrex Corporation were worth $13,703,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of CBM. Schwab Charles Investment Management Inc. boosted its stake in Cambrex Corporation by 3.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 150,109 shares of the biotechnology company’s stock valued at $8,970,000 after buying an additional 4,582 shares in the last quarter. Texas Permanent School Fund boosted its stake in Cambrex Corporation by 1.5% in the second quarter. Texas Permanent School Fund now owns 23,777 shares of the biotechnology company’s stock valued at $1,421,000 after buying an additional 358 shares in the last quarter. Moody Aldrich Partners LLC boosted its stake in Cambrex Corporation by 144.8% in the second quarter. Moody Aldrich Partners LLC now owns 31,075 shares of the biotechnology company’s stock valued at $1,857,000 after buying an additional 18,380 shares in the last quarter. Palouse Capital Management Inc. acquired a new stake in Cambrex Corporation during the second quarter valued at approximately $240,000. Finally, Kornitzer Capital Management Inc. KS boosted its stake in Cambrex Corporation by 67.2% in the second quarter. Kornitzer Capital Management Inc. KS now owns 75,040 shares of the biotechnology company’s stock valued at $4,484,000 after buying an additional 30,170 shares in the last quarter. Hedge funds and other institutional investors own 98.28% of the company’s stock.

Cambrex Corporation (NYSE CBM) opened at 52.60 on Thursday. The stock’s 50 day moving average price is $58.87 and its 200 day moving average price is $55.49. Cambrex Corporation has a 12 month low of $38.30 and a 12 month high of $62.95. The firm has a market capitalization of $1.71 billion, a PE ratio of 20.02 and a beta of 2.28.

Cambrex Corporation (NYSE:CBM) last issued its earnings results on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, meeting the consensus estimate of $0.76. The company had revenue of $134.55 million during the quarter, compared to analysts’ expectations of $136.82 million. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The business’s revenue for the quarter was up 13.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.68 EPS. Equities research analysts expect that Cambrex Corporation will post $3.08 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Granite Investment Partners LLC Has $13.70 Million Position in Cambrex Corporation (CBM)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/10/granite-investment-partners-llc-has-13-70-million-position-in-cambrex-corporation-cbm.html.

CBM has been the topic of several research analyst reports. BidaskClub upgraded Cambrex Corporation from a “hold” rating to a “buy” rating in a research report on Friday, August 4th. Zacks Investment Research cut Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Finally, ValuEngine cut Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $64.00.

In other Cambrex Corporation news, CEO Steven M. Klosk sold 12,000 shares of the company’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $54.19, for a total transaction of $650,280.00. Following the completion of the sale, the chief executive officer now owns 95,328 shares in the company, valued at approximately $5,165,824.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Leon J. Hendrix, Jr. sold 20,656 shares of the company’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $55.95, for a total transaction of $1,155,703.20. Following the sale, the director now owns 74,662 shares of the company’s stock, valued at approximately $4,177,338.90. The disclosure for this sale can be found here. Insiders have sold a total of 70,656 shares of company stock valued at $4,064,423 in the last quarter. Corporate insiders own 2.48% of the company’s stock.

About Cambrex Corporation

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.